Igc pharma announces calma phase 2 trial expansion with the addition of canadian hamilton health sciences

Potomac, md / access newswire / march 20, 2025 / igc pharma, inc. ("igc", or the "company") (nyse american:igc) today announced the expansion of its ongoing phase 2 calma trial for igc-ad1 with the addition of a new clinical site at hamilton health sciences (hhs) in ontario, canada. this expansion marks a key milestone in igc pharma's strategy to advance igc-ad1 toward commercialization, accelerating patient enrollment and expanding the company's clinical footprint.
IGC Ratings Summary
IGC Quant Ranking